Cited by 156Diabetes Treatment and ManagementAtherosclerosis and Cardiovascular DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice

Open access

Ta, Nga N, Schuyler, Corinne A, Li, Yanchun, Lopes-Virella, Maria F, Huang, Yan·2011·Journal of Cardiovascular Pharmacology

DOI 10.1097/fjc.0b013e31821e5626PMC PMC3155015

Open this paper in CoChat — free account

Abstract

Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of antidiabetic compounds, are effective in the treatment of hyperglycemia. Because atherosclerosis-related cardiovascular diseases are the major complications of diabetes, it is important to determine the effect of DPP-4 inhibitors on atherosclerosis. In this study, nondiabetic and diabetic apolipoprotein E-deficient mice were treated with DPP-4 inhibitor alogliptin for 24 weeks, and atherosclerotic lesions in aortic origins were examined. Results showed that diabetes significantly increased atherosclerotic lesions, but alogliptin treatment reduced atherosclerotic lesions in diabetic mice. Metabolic studies showed that diabetes increased plasma glucose and that alogliptin treatment reduced glucose. Furthermore, immunohistochemistry study showed that diabetes increased interleukin-6 (IL-6) and IL-1β protein expression in atherosclerotic plaques, but alogliptin treatment attenuated diabetes-augmented IL-6 and IL-1β expression. In consistence with the observations from the mouse models, our in vitro studies showed that alogliptin-inhibited toll-like receptor 4 (TLR-4)-mediated upregulation of IL-6, IL-1β, and other proinflammatory cytokines by mononuclear cells. Taken together, our findings showed that alogliptin-inhibited atherosclerosis in diabetic apolipoprotein E-deficient mice and that the actions of alogliptin on both glucose and inflammation may contribute to the inhibition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/fjc.0b013e31821e5626

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Increased Toll-Like Receptor (TLR) Activation and TLR Ligands in Recently Diagnosed Type 2 Diabetic Subjects
Dasu, M. R., Devaraj, S., Park, S., & Jialal, I. (2010) · Diabetes Care · doi:10.2337/dc09-1799 · Cited by 572
Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV
Feng, J., Zhang, Z., Wallace, M. B., Stafford, J. A., Kaldor, S. W., Kassel, D. B., Navre, M., Shi, L., Skene, R. J., Asakawa, T., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070104l · Cited by 409
Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice
Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S. M., Wakino, S., Noh, G. J., Palinski, W., Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.365 · Cited by 389
CD26: a surface protease involved in T-cell activation
Fleischer, B. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90316-6 · Cited by 329
Application of Photoshop-based Image Analysis to Quantification of Hormone Receptor Expression in Breast Cancer
Lehr, H., Mankoff, D. A., Corwin, D., Santeusanio, G., & Gown, A. M. (1997) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549704501112 · Cited by 308
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control
DeFronzo, R. A., Fleck, P. R., Wilson, C., Mekki, Q. A., & on behalf of the Alogliptin Study 010 Group (2008) · Diabetes Care · doi:10.2337/dc08-1035 · Cited by 227
TLR Signaling: An Emerging Bridge from Innate Immunity to Atherogenesis
Michelsen, K. S., Doherty, T. M., Shah, P. K., & Arditi, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.5901 · Cited by 211
Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
Ferreira, L., Teixeira‐Lemos, E., Pinto, F., Parada, B., Mega, C., Vala, H., Pinto, R. M. A., Garrido, P., Sereno, J., Fernandes, R., et al. (2010) · Mediators of Inflammation · doi:10.1155/2010/592760 · Cited by 196
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Ulrich, W., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 174
Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice
Lin, R.-Y., Choudhury, R. P., Cai, W., Lu, M. M., Fallon, J. T., Fisher, E. A. A., & Vlassara, H. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00050-9 · Cited by 169
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
Pratley, R. E., Reusch, J. E. B., Fleck, P. R., Wilson, C., Mekki, Q. A., & on behalf of the Alogliptin Study 009 Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903156111 · Cited by 132
The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.
Augustyns, K., Bal, G., Thonus, G., Belyaev, A., Zhang, X. M., Bollaert, W., Lambeir, A., Durinx, C., Goossens, F. J., & Haemers, A. (1999) · PubMed · Cited by 131
The Unique Properties of Dipeptidyl-peptidase IV (DPP IV I CD26) and the Therapeutic Potential of DPP IV Inhibitors
Augustyns, K., Bala, G., Thonusa, G., Belyaeva, A., Zhanga, X. M., Bollaerta, W., Lambeirb, A. M., Durinxb, C., Goossensb, F., & Haemersa, A. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220208213543 · Cited by 125
Expression of Interleukin-6 in Atherosclerotic Lesions of Male ApoE-Knockout Mice
Sukovich, D. A., Kauser, K. Z., Shirley, F. D., DelVecchio, V., Halks‐Miller, M., & Rubanyi, G. M. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.9.1498 · Cited by 124
Imatinib Attenuates Diabetic Nephropathy in Apolipoprotein E-Knockout Mice
Lassila, M., Jandeleit-Dahm, K. A. M., Seah, K. K., Smith, C. M., Calkin, A. C., Allen, T. J., & Cooper, M. E. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004050392 · Cited by 117
Functional role of CD26 on human B lymphocytes
Bühling, F., Junker, U., Reinhold, D., Neubert, K., Jäger, L., & Ansorge, S. (1995) · Immunology Letters · doi:10.1016/0165-2478(94)00230-o · Cited by 112
Do Glucose and Lipids Exert Independent Effects on Atherosclerotic Lesion Initiation or Progression to Advanced Plaques?
Kanter, J. E., Johansson, F., LeBoeuf, R. C., & Bornfeldt, K. (2007) · Circulation Research · doi:10.1161/01.res.0000259589.34348.74 · Cited by 112
Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes
Gupta, R., Walunj, S. S., Tokala, R. K., Parsa, K. V. L., Singh, S. K., & Pal, M. (2009) · Current Drug Targets · doi:10.2174/138945009787122860 · Cited by 105
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes
Ta, N., Li, Y., Schuyler, C. A., Lopes-Virella, M. F., & Huang, Y. Q. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.08.064 · Cited by 96
Self-citation
Lipopolysaccharide and Peptidoglycan: CD14-Dependent Bacterial Inducers of Inflammation
Rietschel, E., Schletter, J., Weidemann, B., El‐Samalouti, V. T., Mattern, T., Zähringer, U., Seydel, U., Brade, H., Flad, H.-D., Kusumoto, S., et al. (1998) · Microbial Drug Resistance · doi:10.1089/mdr.1998.4.37 · Cited by 89
Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17β-estradiol
Tse, J., Martin-McNulty, B., Halks‐Miller, M., Kauser, K. Z., DelVecchio, V., Vergona, R. A., Sullivan, M. E., & Rubanyi, G. M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00325-6 · Cited by 84
Cross‐linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen‐activated protein kinase
Hegen, M., Kameoka, J., Dong, R., Schlossman, S. F., & Morimoto, C. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00053.x · Cited by 78
Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)
Saremi, A., Anderson, R. J., Luo, P., MORITZ, T. E., Schwenke, D. C., Allison, M., & Reaven, P. D. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.031 · Cited by 77
Why does diabetes increase atherosclerosis? I don’t know!
Goldberg, I. J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22826 · Cited by 64
Alogliptin
Scott, L. J. (2010) · Drugs · doi:10.2165/11205080-000000000-00000 · Cited by 61
Effects of chronic administration of alogliptin on the development of diabetes and β ‐cell function in high fat diet/streptozotocin diabetic mice
Zhang, X., Wang, Z., Huang, Y. Q., & Wang, J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01354.x · Cited by 57
Self-citation
Inhibitors of Dipeptidyl Peptidase IV (DP IV, CD26) Specifically Suppress Proliferation and Modulate Cytokine Production of Strongly CD26 Expressing U937 Cells
Reinhold, D., Bank, U., Bühling, F., Kähne, T., Kunt, D., Faust, J., Neubert, K., & Ansorge, S. (1994) · Immunobiology · doi:10.1016/s0171-2985(11)80412-2 · Cited by 57
Macrophage-foam cell formation in streptozotocin-induced diabetic mice: Stimulatory effect of glucose
Hayek, T., Hussein, K., Aviram, M., COLEMAN, R., Keidar, S., PAVOLTZKY, E., & KAPLAN, M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.02.018 · Cited by 54
Combination treatment with alogliptin and voglibose increases active GLP‐1 circulation, prevents the development of diabetes and preserves pancreatic beta‐cells in prediabetic db/db mice
Moritoh, Y., Takeuchi, K., & Hazama, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01156.x · Cited by 49
High glucose enhances lipopolysaccharide-stimulated CD14 expression in U937 mononuclear cells by increasing nuclear factor κB and AP-1 activities
Nareika, A., Im, Y., Game, B. A., Slate, E. H., Sanders, J. J., London, S. D., Lopes-Virella, M. F., & Huang, Y. Q. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0145 · Cited by 47
Self-citation
Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: The pivotal role of vasoactive intestinal peptide
Jungraithmayr, W., Meester, I. D., Matheeussen, V., İnci, İ., Augustyns, K., Scharpé, S., Weder, W., & Korom, S. (2009) · Peptides · doi:10.1016/j.peptides.2009.12.012 · Cited by 46
Cardiovascular outcomes among participants with diabetes in the recent large statin trials
Armitage, J., & Bowman, L. J. (2004) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000137219.31407.16 · Cited by 35
Dipeptidyl peptidase IV (DP IV, CD26) is involved in regulation of DNA synthesis in human keratinocytes
Reinhold, D., Vetter, R., Mnich, K., Bühling, F., Lendeckel, U., Born, I., Faust, J., Neubert, K., Gollnick, H. P. M., & Ansorge, S. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00502-x · Cited by 35
Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation
Sundararaj, K. P., Samuvel, D. J., Li, Y., Nareika, A., Slate, E. H., Sanders, J. J., Lopes-Virella, M. F., & Huang, Y. Q. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0108064 · Cited by 35
Self-citation
Relation between interleukin-6 level and subclinical intracranial large-artery atherosclerosis
Hoshi, T., Kitagawa, K., Yamagami, H., Furukado, S., Hougaku, H., & Hori, M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.05.013 · Cited by 35
Pre‐exposure to high glucose augments lipopolysaccharide‐stimulated matrix metalloproteinase‐1 expression by human U937 histiocytes
Maldonado, A., He, L., Game, B. A., Nareika, A., Sanders, J. J., London, S. D., Lopes-Virella, M. F., & Huang, Y. Q. (2004) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2004.00756.x · Cited by 30
Self-citation
Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice
Goldberg, I. J., Isaacs, A. J., Sehayek, E., Breslow, J. L., & Huang, L.-S. (2003) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.09.014 · Cited by 20
Human mononuclear phagocyte-associated antigens
Waldrep, J. C., Mohanakumar, T., & Kaplan, A. M. (1981) · Cellular Immunology · doi:10.1016/0008-8749(81)90307-5 · Cited by 17
Administration of Pioglitazone in Low-Density Lipoprotein Receptor-Deficient Mice Inhibits Lesion Progression and Matrix Metalloproteinase Expression in Advanced Atherosclerotic Plaques
He, L., Game, B. A., Nareika, A., Garvey, W. T., & Huang, Y. Q. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000248831.21973.c4 · Cited by 16
Self-citation
The effect of fibrate–statin combination therapy on cardiovascular events: a retrospective cohort analysis
Wierzbicki, A. S., Morrell, J., Hemsley, D., McMahon, Z., Crook, M. A., & Wray, R. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.503429 · Cited by 13
The PROactive study: Pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes
Pratley, R. E. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0051-6 · Cited by 10
Eplerenone does not attenuate diabetes-associated atherosclerosis
Koh., P. J., Koı̈tka, A., Cooper, M. E., & Allen, T. J. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832bd284 · Cited by 7

Research works printed but not linked: 1

Jungraithmayr, 31, Peptides, 585-, 591

Sorted by citations

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 255
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
Zhong, J., Rao, X., & Rajagopalan, S. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.012 · Cited by 209
The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis
Waumans, Y., Baerts, L., Kehoe, K., Lambeir, A., & Meester, I. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00387 · Cited by 194
DPP4 in Cardiometabolic Disease
Zhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 190
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175

See all 156

Authors: Ta, N. N., Schuyler, C. A., Li, Y., Lopes-Virella, M. F., & Huang, Y.
Affiliations: Medical University of South Carolina (US)
Corresponding author: Huang, Yan
ORCID: Lopes-Virella, Maria F
Huang, Yan
Venue: Journal of Cardiovascular Pharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-08
Volume: 58
Issue: 2
Pages: 157-166
ISSN: 0160-2446 (ISSN-L)
DOI: 10.1097/fjc.0b013e31821e5626
PMC: PMC3155015
OpenAlex: W2059903872
Cited by: 156
References: 42
Citations by year: 2025: 2 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 10 · 2019: 6 · 2018: 13 · 2017: 10 · 2016: 16 · 2015: 22 · 2014: 17 · 2013: 23 · 2012: 13
FWCI: 13.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Cardiovascular Pharmacology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Dental and Craniofacial Research (R01DE016353, DE016353)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: alogliptin, DPP-4 inhibitors, atherosclerosis, diabetes mellitus, ApoE-deficient mice, interleukin-6, IL-1β, TLR4, inflammation, glucose, mononuclear cells, aortic atherosclerotic lesions
MeSH terms: Interleukin-6 Inhibitors, Animals, Apolipoproteins E, Blood Glucose, Cholesterol, Diabetes Mellitus, Experimental, Enzyme-Linked Immunosorbent Assay, Humans, Male, Piperidines, Triglycerides, Uracil, Mice, Knockout, Dipeptidyl Peptidase 4, U937 Cells, Atherosclerosis, Mice, Interleukin-1beta, Dipeptidyl-Peptidase IV Inhibitors, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks